top of page

Our Research Partners & Clinical Trials

At Duke...there is HOPE!

We partner with doctors and researchers at the Duke Brain Tumor Center to fund innovative research on the most aggressive forms of brain cancer.


Innovative research is not federally funded until enough data has been collected. For this reason, private funding is critical for clinical trial research to move forward. With private funding, our research partners at Duke hope to bear enough promising results to receive federal grants worth tens of millions of dollars – grants that will take KMF funded clinical trials to patients on a nationwide level.

Our Clinical Trials

Our 2022 & 2023 gifts to Duke were used to fund three FDA-approved clinical trials for brain cancer patients with high-grade glioma & Glioblastoma, just like the one our namesake Knox had.


Trial 1:

The trial is opened for enrollment to recurrent high-grade glioma patients at Duke as of July 24th, 2023. Upon promising results, doctors at Duke hope to make it available to patients at Stanford, UC San Diego, NYU, and the University of Washington.

FLIrT is an exciting new FDA-approved trial evaluating if PROZAC can enhance the effect of chemotherapy against recurrent high-grade brain tumors.

PROZAC is a drug commonly used to treat depression. PROZAC is also already widely available, inexpensive, and has a well-understood safety profile. New research shows that PROZAC can also make tumors more sensitive to chemotherapy.


The findings of this trial are very exciting, because they could potentially be rapidly translated into routine clinical practice.


Trial 2:

The team at Duke is studying ways to make immunotherapy highly individualized to a patient’s body and their tumor.

They’re is using tumor samples removed at the time of surgery to grow and strengthen the patient’s native immune cells outside of the body (in the lab).

The team will give the strengthened immune cells back to patients, to prompt the patient’s own immune system to assist in destroying the tumor.


Trial 3:

Doctors are evaluating the efficacy of a drug called Evolocumab to make cancer cells more visible to the immune system.

Evolocumab (Evo) is a drug commonly used to treat high cholesterol.

PESKe will assess how well Evo can penetrate the blood-brain barrier and make tumor cells more visible to the immune system & vulnerable to treatment.

This content was reviewed by Dr. Mustafa Khasraw, MD of the Duke Brain Tumor Center.

Our Research Advisory Board

Dr. Hotchkiss (L) and Dr. Desjardins (R) speaking with attendees at our Third Annual Fundraising Event, Night For Knox, in April 2023.


Dr. Hotchkiss (L) and KMF CEO Becky Martin (R) at our Inaugural Golf Against Gliomas Tournament in September 2023.

bottom of page